3 results
Approved WMOWill not start
To assess the safety and tolerability profile of durvalumab monotherapy, durvalumab + novel oncology therapy, durvalumab + chemotherapy, anddurvalumab + novel oncology therapy + chemotherapy combinations
Approved WMOCompleted
The primary objective of this study is:• To evaluate whether simtuzumab (formally referred to as GS-6624) is effective at preventing the progression of liver fibrosis in subjects with PSC.The secondary objectives of this study include the following…
Approved WMORecruiting
To collect clinical and device performance outcomes data with the ACURATE neo2* Transfemoral Aortic Valve System as used inroutine clinical practice for the treatment of severe calcific aortic stenosis.